Renata PLC (DSE:RENATA)

Bangladesh flag Bangladesh · Delayed Price · Currency is BDT
448.60
+4.00 (0.90%)
At close: Mar 2, 2026
-11.75%
Market Cap 50.99B
Revenue (ttm) 44.26B
Net Income (ttm) 2.54B
Shares Out 114.70M
EPS (ttm) 22.11
PE Ratio 20.11
Forward PE 14.97
Dividend 5.50 (1.24%)
Ex-Dividend Date Nov 18, 2025
Volume 22,627
Average Volume 58,661
Open n/a
Previous Close 444.60
Day's Range 445.00 - 458.40
52-Week Range 372.00 - 548.00
Beta -0.09
RSI 50.12
Earnings Date Apr 28, 2026

About Renata

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pedia... [Read more]

Industry Pharmaceutical Preparations
Founded 1972
Employees 8,366
Stock Exchange Dhaka Stock Exchange
Ticker Symbol RENATA
Full Company Profile

Financial Performance

In fiscal year 2025, Renata's revenue was 42.89 billion, an increase of 13.74% compared to the previous year's 37.71 billion. Earnings were 2.22 billion, a decrease of -38.58%.

Financial Statements

News

There is no news available yet.